IKNA - Ikena Oncology, Inc.
IEX Last Trade
1.565
0.025 1.597%
Share volume: 11,956
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$1.54
0.03
1.62%
Fundamental analysis
22%
Profitability
25%
Dept financing
4%
Liquidity
75%
Performance
10%
Performance
5 Days
-8.38%
1 Month
-10.53%
3 Months
-11.05%
6 Months
-6.71%
1 Year
-26.79%
2 Year
-46.32%
Key data
Stock price
$1.56
DAY RANGE
$1.50 - $1.57
52 WEEK RANGE
$1.29 - $2.11
52 WEEK CHANGE
-$24.26
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Mark Manfredi
Region: US
Website: ikenaoncology.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ikenaoncology.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Ikena Oncology, Inc. focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
Recent news